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Background: Estimated glomerular filtration rate (eGFR) levels have been shown to predict atherosclerotic vascular
disease hospitalization and mortality. We sought to investigate the role of renal function in the prediction of 10-
year atherosclerotic vascular hospitalization and deaths in an unselected population of elderly women in and
compared these predictions to Framingham equations.
Methods: Complete 10-year verified mortality and hospitalization discharge records for atherosclerotic vascular
disease was collected for a prospective study of 1,239 unselected female subject’s≥ 70 from the Calcium Intake
Fracture Outcome Study (CAIFOS) with 10 years of follow-up. eGFR was compared to the current Framingham risk
scores.
Results: The eGFR at baseline using the Modification of Diet in Renal Disease Study (MDRD) equation was
65.2 ± 14.5 mL/min/1.73 m2 and 66.3 ± 13.5 mL/min/1.73 m2 using the Chronic Kidney Disease EPIdemiology (CKD-
EPI) equation. Over 10 years 30% of participants sustained an ASVD hospitalization or death. For every standard
deviation (SD) reduction in eGFR using MDRD the odds ratio (OR) for ASVD hospitalization and deaths increased by
1.34 (1.18-1.53), P< 0.001and 1.31 (1.14-1.50), P< 0.001 in a model adjusted for Framingham 10-year general
cardiovascular risk. Addition of eGFR by the MDRD equation to Framingham risk factors improved the net
reclassification index by 5.9%, P = 0.018 and the integrated discrimination improvement by 0.010 ± 0.003, P< 0.001
Similar results were seen using the CKD-EPI equation.
Conclusion: Estimated glomerular filtration rate predicts ASVD outcomes independently of Framingham risk score
predictions in elderly women and improves clinical prediction particularly of early ASVD.Background
Atherosclerotic vascular disease (ASVD) remains a lead-
ing cause of morbidity and mortality. The development
of equations to estimate renal function using age and
serum creatinine has shown that estimated glomerular
filtration rate (eGFR) is an important predictor of clin-
ical ASVD outcomes, especially mortality, when eGFR
falls below 60 ml/min/1.73 m² [1-3] and is associated
with all cause and cardiovascular mortality in general* Correspondence: joshua.lewis@uwa.edu.au
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reproduction in any medium, provided the orpopulation cohorts [4]. Many studies have been restricted
to study of patients with eGFR below 60 ml/min/1.73 m²
compared to above 60 ml/min/1.73 m² [5-9]. However the
effects of earlier stages of renal function deterioration on
ASVD outcomes have been less well studied particularly
in the elderly [10]. Thus there is uncertainty as to whether
mild renal dysfunction may have adverse cardiovascular
effects independent of known risk factors in this
population.
Two methods of calculating eGFR have been devel-
oped the “175” Modification of Diet in Renal Disease
(MDRD) equation [11] and the CKD-EPI equation [2].
In middle aged populations comparison of the MDRD
equation to the CKD-EPI equation to predict mortalitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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advantages over the MDRD equation [2,12,13].
The study design employed used both the revised MDRD
and the CKD-EPI equations to examine the relationship of
eGFR to atherosclerotic vascular disease in unselected eld-
erly women using complete adjudicated hospital record dis-
charge data from the Western Australian Data Linkage
System. In addition the eGFR calculations were compared
to the Framingham general cardiovascular risk model.
Methods
Study population
The participants were recruited in 1998 and followed for
10 years. At baseline they entered a 5-year prospective,
randomized, controlled trial of oral calcium supplements
to prevent osteoporotic fractures [14]. The participants
were ambulant and did not have any medical conditions
likely to influence 5-year survival. They were only
excluded if they were receiving bone-active agent, in-
cluding hormone replacement therapy. Participants were
similar in terms of baseline disease burden and medica-
tions compared to the whole population of this age but
they were more likely to be from higher socio-economic
groups [14]. They were subsequently asked to enter a 5-
year follow-up study of ageing.
They were recruited from the Western Australian gen-
eral population of women aged over 70 years by mail
using the electoral roll a requirement of citizenship.
Over 99% of Australians of this age are registered on the
roll. Of the 5,586 women who responded to a letter in-
viting participation 1,510 women were willing and eli-
gible and of these 1,500 women were recruited for the
study. In the first 5 years of the study participants
received 1.2 g of elemental calcium as calcium carbonate
daily or a matched placebo. The Human Ethics Commit-
tee of the University of Western Australia approved the
study.
Renal function assessment
Baseline renal function was determined in 1,239 women.
Serum was collected after an overnight fast and serum
creatinine analysed in 2005 using an isotope dilution
mass spectrometry (IDMS) traceable Jaffe kinetic assay
for creatinine on a Hitachi 917 analyzer (Roche Diagnos-
tics GmbH, Mannheim Germany). The estimated GFR
calculated in mL/min/1.73 m2 using the revised “175”
MDRD study equation was; 175 (standardized serum
creatinine (Scr) in mg/dL) -1.154 x (Age) -0.203 x 0.742
with creatinine values entered in mg/dL into the equa-
tion [11,15,16]. The estimated GFR calculated using the
CKD-EPI equations was; Scr ≤ 0.7 mg/dL = 144 × (Scr/
0.7)-0.329 × (0.993) Age or Scr> 0.7 mg/dL = 144 × (Scr/
0.7)-1.209 × (0.993) Age with creatinine values entered in
mg/dL into the equations [2]. Estimated GFR wasseparated into Chronic Kidney Disease (CKD) categories
as defined by the kidney disease outcomes quality initia-
tive (K/DOQI) classification [17].
Framingham risk score
The 10-year Framingham general cardiovascular disease
risk score was calculated using age, previous diabetes,
body mass index, current smoking status and the un-
treated systolic blood pressure using the equation and
estimated regression coefficients developed by D'Agos-
tino et al. 2008 [18].
The Framingham risk score (FRS) equation was;
FRS = 1–0.94833exp(2.72107*ln(Age)+0.51125*ln(BMI)+2.81291*ln
(SBP)+0.61868*(Currentsmoker)+0.77763*(Diabetes)-26.0145).
The risk scores were then confirmed using the online
calculator prepared by R.B. D’Agostino and M.J. Pencina
based on the publication by D’Agostino et al. [18].
Baseline ASVD risk assessment
Previous atherosclerotic vascular disease was determined
from the complete hospital discharge data from 1980–
1998 and were defined using diagnosis codes from the
International Classification of Diseases, Injuries and
Causes of Death Clinical Modification (ICD-9-CM) [19].
These codes included: ischemic heart disease (ICD-9-
CM codes 410–414); heart failure (ICD-9-CM code
428); cerebrovascular disease excluding hemorrhage
(ICD-9-CM codes 433–438); and peripheral arterial dis-
ease (ICD-9-CM codes 440–444). The participants pro-
vided their previous medical history and current
medications verified by their General Practitioner. These
data were coded using the International Classification of
Primary Care – Plus (ICPC-Plus) method [20]. The cod-
ing methodology allows aggregation of different terms
for similar pathologic entities as defined by the ICD-10
coding system. These data were then used to determine
the presence of diabetes at baseline.
At baseline weight was assessed using digital scales
with participants wearing light clothes and no shoes,
height was assessed using a stadiometer and the body
mass index was calculated in kg/m2. Blood pressure was
measured in 1,205 participants on the right arm with a
mercury column Manometer using an adult cuff after
the patient had been seated and resting for at least 5
minutes, the average of 3 such measurements was
obtained.
Incident ASVD outcome assessment
The primary outcome was an atherosclerotic vascular
disease event causing hospitalization or death. First-time
atherosclerotic hospitalizations were retrieved from the
Western Australian Data Linkage System (WADLS) for
each of the study participants from 1998 until 10 years
after their baseline visit. WADLS provides a complete
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at hospital discharge using coded data form all hospitals
in Western Australia. Cause of death was retrieved from
the coded death certificate using information in Parts 1
and 2 of the death certificate, all diagnosis text fields
from the death certificate were used to ascertain the
cause(s) of deaths where these data were not yet avail-
able from the WADLS. Atherosclerotic events were
defined using primary diagnosis codes from the Inter-
national Classification of Diseases, Injuries and Causes
of Death Clinical Modification (ICD-9-CM) [19] and the
International Statistical Classification of Diseases and
Related Health Problems, 10th Revision, Australian
Modification (ICD-10- AM) [21]. These codes included:
ischemic heart disease (ICD-9-CM codes 410–414 and
ICD-10-AM codes I20-I25); heart failure (ICD-9-CM
code 428 and ICD-10-AM code I50); cerebrovascular
disease excluding hemorrhage (ICD-9-CM codes 433–
438 and ICD-10-AM codes I63-69, G45.9); and periph-
eral arterial disease (ICD-9-CM codes 440–444 and
ICD-10-AM codes I70-74).
Statistical analysis
The primary outcome was the odds ratio of the time to
first atherosclerotic vascular hospitalization or death up
to ≤ 10 years after the baseline visit. Covariates were
entered into the model as continuous variables with the
exception of current smoking and diabetes, which were
entered as dichotomous (y/n) variables. All continuous
variables were naturally logarithmically transformed to
improve discrimination and calibration of the models
and to minimize the influence of extreme observations.
No interactions between baseline confounders were
detected. The effect of eGFR on reclassification of risk
was assessed using net reclassification improvement and
integrated discrimination improvement [22,23]. Using
the Framingham risk factors participants were classified
into three 10-year risk categories of ASVD, low (< 15%),Table 1 Baseline characteristics of the total cohort and those
disease (ASVD) hospitalization and mortality
Baseline Characteristics All participants (n = 1,239)
Age (years) 75.20 ± 2.71
Body mass index (kg/m2) 27.21 ± 4.68
Systolic blood pressure (mm Hg) 137.76± 18.00
Current smoker (yes/no) 6 (0.0)
Diabetes (yes/no) 85 (6.9)
Prevalent ASVD (yes/no) 150 (12.1)
MDRD eGFR (mL/min/1.73 m2) 65.20 ± 14.54
CKD-EPI eGFR (mL/min/1.73 m2) 66.26 ± 13.47
Results are mean ± SD or number and (%). P values are a comparison of those with
squared test where appropriate. ASVD atherosclerotic vascular disease, eGFR estima
CKD-EPI Chronic Kidney Disease EPIdemiology.intermediate (15%-30%) or high (≥ 30%) for ASVD hos-
pitalizations and deaths. These risk categories are based
on the median predicted risk by Framingham risk factors
(30%). The participants were then reclassified into new
risk categories with the addition of eGFR to the model
and the net reclassification improvement (NRI) and inte-
grated discrimination improvement (IDI) were calcu-
lated. Results are presented as odds ratio (OR) and
associated 95% confidence intervals. P values less than
0.05 in two tailed testing were considered statistically
significant. The data was analysed using SPSS (version
15; SPSS Inc., Chicago, IL), STATA (version 11 Stata-
Corp LP, College Station, TX) and SAS (Version 9, SAS
Institute Inc., Chicago, IL).
Results
The mean age of the 1,239 participants was 75.2± 2.7 years
and the mean eGFR by the MDRD and the CKD-EPI
equations was 65.2± 14.5 and 66.3± 13.5 mL/min/1.73 m2
respectively, 63% and 66% of the participants had an
eGFR≥ 60 mL/min/1.73 m2 by the MDRD and CKD-EPI
equations. The baseline characteristics of the 1,239 partici-
pants are shown in Table 1. Participants who sustained an
ASVD event over the 10 years of the study had lower
baseline values for eGFR by the MDRD and the CKD-EPI
equations and higher values for age, body mass index,
prevalent diabetes, systolic blood pressure and previous
history of ASVD.
The relationship between each individual’s atheroscler-
otic vascular disease hospitalizations and mortality out-
comes and their eGFR, total Framingham score and
each component of that score are shown in Table 2. As
expected smoking, diabetes and prevalent ASVD showed
the largest effects, however because of small numbers
current smoking was not significant. eGFR by both
methods compared well to the other continuous risk fac-
tors systolic blood pressure and BMI. The Kaplan Meir
data for ASVD hospitalization and death by categories ofwith and without subsequent atherosclerotic vascular
With ASVD (n = 369) Without ASVD (n = 870) P value
75.73 ± 2.87 74.97 ± 2.61 < 0.001
27.82 ± 5.29 26.95 ± 4.38 0.003
140.73 ± 18.27 136.54 ± 17.76 < 0.001
3 (0.0) 3 (0.0) 0.371
38 (10.3) 47 (5.4) 0.002
90 (24.4) 60 (6.9) < 0.001
62.42 ± 13.72 66.37 ± 14.73 < 0.001
63.54 ± 13.76 67.42 ± 13.19 < 0.001
and without ASVD hospitalizations at 10 years by univariate ANOVA or Chi
ted glomerular filtration rate, MDRD Modification of Diet in Renal Disease and
Table 2 Odds ratios for atherosclerotic vascular disease hospitalizations and mortality by individual variables used in
the Framingham risk calculators and eGFR
Characteristics (n = 1,239) SD Odds Ratio (95% CI) P value
Age (years) 2.71 1.32 (1.17-1.49) <0.001
Body mass index (kg/m2) 4.68 1.20 (1.06-1.35) 0.003
Current smoker yes/no 2.37 (0.48-11.79) 0.292
Diabetes yes/no 2.01 (1.29-3.14) 0.002
Prevalent ASVD yes/no 4.36 (3.05-6.20) < 0.001
Systolic blood pressure (mm Hg) 18.00 1.26 (1.11-1.43) < 0.001
MDRD eGFR (mL/min/1.73 m2) 14.54 1.34 (1.18-1.53) < 0.001
CKD-EPI eGFR (mL/min/1.73 m2) 13.47 1.34 (1.18-1.52) < 0.001
Framingham risk score 10-year risk (%) 8.58 1.45 (1.28-1.65) < 0.001
Results are unadjusted OR (mean 95% CI) by baseline standard deviation for continuous variables or yes/no for categorical variables. ASVD indicates
atherosclerotic vascular disease, eGFR estimated glomerular filtration rate, MDRD Modification of Diet in Renal Disease equation and CKD-EPI Chronic Kidney
Disease EPIdemiology equation.
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in Figure 1. Individuals with baseline calculated eGFR>
than 90 mL/min/1.73 m2 had a disease free survival of
81% whereas individuals with an eGFR< than 45 mL/
min/1.73 m2 had a disease free survival of 54%.
Next the Framingham risk score and eGFR calculated
by the two methods were examined for independent pre-
dictive ability for ASVD risk by inclusion of both vari-
ables in the same model to predict ASVD outcomes
(Table 3). In each of the comparisons both Framingham
risk scores and eGFR calculations per SD were signifi-
cantly associated with ASVD hospitalization or deaths
and the combined hospitalizations and deaths when
adjusted for the other value. To put these findings in a
clinical context the effect of eGFR on ASVD hospitalization
and deaths was calculated using 10 mL/min/1.73 m2
decreases in eGFR as the unit of change. Analysis of 1,089
participants without ASVD at baseline showed that whilea
Figure 1 Kaplan Meier survival curves for ASVD hospitalizations and
categories of eGFR by the MDRD equation; blue line <45 mL/min/1.7
line 60–89 mL/min/1.73 m2 (n = 722) and black line ≥90 mL/min/1.73
year risk (n = 128), green line 15-29% 10-year risk (n = 649) and grey lthe association between eGFR and ASVD hospitalizations
and deaths remained significant it was reduced (Figure 2).
The Net Reclassification Improvement (NRI) compar-
ing the 10-year Framingham general cardiovascular risk
factors and the MDRD eGFR calculation is shown in
Table 4. Using the CKD-EPI eGFR calculation the NRI
was 5.1% P= 0.040 and the IDI was 0.015 ± 0.003,
P< 0.001.
Discussion
These data show a relationship between reduction in
eGFR by both the MDRD and CKD-EPI equations and
increased long-term ASVD-related hospitalization and
mortality in elderly women. This association was inde-
pendent of the method of calculation of eGFR and ana-
lytical approach using either per SD reduction or per
10 mL/min/1.73 m2 reductions in eGFR. Although
slightly diminished by the inclusion of the Framinghamb
deaths dichotomized by a) K/DOQI chronic kidney disease
3 m2 (n= 71), green line 45–59 mL/min/1.73 m2 (n = 388), grey
m2 (n= 58) and b) Framingham predicted risk, blue line ≥30% 10-
ine <15% 10-year risk (n = 427).
Table 3 Comparison of eGFR and Framingham risk score
in predicting ASVD outcomes in a model including both
terms
eGFR Framingham
ASVD hospitalizations (n = 307)
MDRD 1.33 (1.15-1.53) 1.48 (1.29-1.69)
CKD-EPI 1.31 (1.15-1.50) 1.47 (1.28-1.68)
ASVD deaths (n = 129)
MDRD 1.29 (1.05-1.57) 1.37 (1.14-1.64)
CKD-EPI 1.32 (1.09-1.59) 1.36 (1.13-1.63)
ASVD events (n = 369)
MDRD 1.31 (1.14-1.50) 1.43 (1.26-1.63)
CKD-EPI 1.30 (1.15-1.48) 1.43 (1.25-1.62)
The results are odds ratio and 95% confidence interval per SD decrease in
eGFR and per SD increase in Framingham risk score includes age, body mass
index, smoking, systolic blood pressure and diabetes. ASVD atherosclerotic
vascular disease, eGFR estimated glomerular filtration rate, MDRD Modification
of Diet in Renal Disease equation, CKD-EPI Chronic Kidney Disease
EPIdemiology equation.
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ing the concept that renal dysfunction may have its dele-
terious effect via pathways independent of otherFigure 2 Framingham risk score-adjusted odds ratio and 95% confide
whole cohort and those free of ASVD at baseline. ASVD atherosclerot
MDRD Modification.traditional risk factors associated with increased ASVD
risk [1].
Compared with an elderly woman with an eGFR of
90 ml/min/1.73 m², an elderly women with eGFR of
60 ml/min/1.73 m² (currently the reporting level for
concern) would be at a 60 - 63% increased risk of long-
term ASVD-associated hospitalization or death inde-
pendent of Framingham risk factors. These findings sup-
port and extend previous studies showing increased risk
in younger patients with an eGFR 60 – 90 ml/min/
1.73 m² [10] . In contrast a recent literature review by
Chang and Kramer found eGFR did not significantly im-
prove the C-index in AUC analysis in addition to the
Framingham equation [24]. These studies however did
not use the newer net reclassification improvement
(NRI) or integrated discrimination improvement (IDI)
metrics which are designed to evaluate improved pre-
dictive ability and are considered to be more powerful
than the C-index for comparing predictive models [25].
If addition of variables to a base model improves assig-
nation of individuals to higher or lower probability of
having an event the NRI and the IDI value can measure
the degree of improvement. The NRI uses clinicallynce interval per 10 ml/min/1.73 m² decrease in eGFR in the
ic vascular disease, eGFR estimated glomerular filtration rate,
Table 4 Reclassification among people who do or do not experience an ASVD hospitalization or death during 10-year
of follow
Framingham predicted risk with eGFR by MDRD equation
Framingham predicted
risk without eGFR






Participants who experienced ASVD hospitalization or death (n= 352)
< 15% 0 3 0
15-30% 6 124 23 26 (7.4%) 23 (6.5%) 3 (0.9%)
≥ 30% 0 17 179
Participants who did not experience ASVD hospitalization or death (n= 852)
< 15% 14 9 0
15-30% 34 439 50 59 (6.9%) 102 (12.0%) 43 (5.0%)
≥ 30% 3 65 238
Net reclassification improvement (NRI) = 5.9% P= 0.018, IDI = 0.010 ± 0.003, P< 0.001. Framingham risk factors included age, body mass index, smoking, systolic
blood pressure and diabetes. ASVD indicates atherosclerotic vascular disease; eGFR estimated glomerular filtration rate and MDRD Modification of Diet in Renal
Disease equation.
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continuous variable. The inclusion of eGFR calculated
by either equation added to the Framingham risk factors
improved the NRI by between 5.1 to 5.9%. Direct com-
parisons to other markers of cardiovascular disease are
difficult due to the differences in study population
demographics, event rates and duration of study how-
ever the overall net reclassification improvement is simi-
lar to the 5.3% NRI observed where C reactive protein
and parental history of myocardial infarct was added to
traditional cardiovascular risk factors for cardiovascular
disease risk prediction [22]. The addition of eGFR to the
Framingham risk scores also improved the IDI by 0.010
- 0.015. These results are comparable to those reported
in a recent study which found that adding eGFR to other
known risk factors improved the IDI by 0.011 [26].
The strengths of this study relate to the complete
person-based linkage of the 1,239 participants for all
atherosclerotic vascular hospitalizations and mortality
using previously validated hospital admission and mor-
tality data from the Western Australian Data Linkage
System that has been used in over 250 publications [27]
as well as the availability of detailed adverse event data.
Limitations of the study are that compared to other
studies the sample size is small and is restricted to eld-
erly women. Second the use of serum creatinine, rather
than serum cystatin C, which has been shown by some
[28-31], but not others [32], to be a stronger predictor of
all-cause and cardiovascular mortality particularly in
older participants. Others have argued that the strong
association of cystatin C with all cause and cardiovascu-
lar mortality may be due to its association with factors
other than GFR such as measures of body size, diabetes
and inflammation [33]. Finally data on the albumin cre-
atinine ratio in these patients was not available a meas-
urement that may add significant predictive data [34].Conclusion
In this population impaired renal function is an inde-
pendent risk for atherosclerotic vascular disease in
addition to Framingham risk factors possibly related to
age-related structural changes in older kidneys resulting
in a reduction in functioning glomeruli.
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